Akoya Biosciences Inc (NASDAQ: AKYA) on Friday, plunged -3.08% from the previous trading day, before settling in for the closing price of $1.30. Within the past 52 weeks, AKYA’s price has moved between $0.93 and $3.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 15.96%. The company achieved an average annual earnings per share of 30.80%. With a float of $20.81 million, this company’s outstanding shares have now reached $49.84 million.
Let’s determine the extent of company efficiency that accounts for 205 employees. In terms of profitability, gross margin is 61.74%, operating margin of -48.22%, and the pretax margin is -59.28%.
Akoya Biosciences Inc (AKYA) Insider Activity
Observing investor behavior towards Medical Instruments & Supplies industry stocks is more important than anything else. The insider ownership of Akoya Biosciences Inc is 58.29%, while institutional ownership is 24.65%. The most recent insider transaction that took place on Jun 11 ’24, was worth 15,630. In this transaction President and CEO of this company sold 7,500 shares at a rate of $2.08, taking the stock ownership to the 224,733 shares. Before that another transaction happened on Jun 06 ’24, when Company’s President and CEO sold 7,500 for $2.01, making the entire transaction worth $15,064. This insider now owns 224,733 shares in total.
Akoya Biosciences Inc (AKYA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.40% during the next five years compared to -23.03% drop over the previous five years of trading.
Akoya Biosciences Inc (NASDAQ: AKYA) Trading Performance Indicators
Akoya Biosciences Inc (AKYA) is currently performing well based on its current performance indicators. A quick ratio of 0.40 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of Akoya Biosciences Inc (AKYA)
Looking closely at Akoya Biosciences Inc (NASDAQ: AKYA), its last 5-days average volume was 3.79 million, which is a jump from its year-to-date volume of 0.66 million. As of the previous 9 days, the stock’s Stochastic %D was 73.10%. Additionally, its Average True Range was 0.12.
During the past 100 days, Akoya Biosciences Inc’s (AKYA) raw stochastic average was set at 13.22%, which indicates a significant decrease from 64.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 123.24% in the past 14 days, which was higher than the 90.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2684, while its 200-day Moving Average is $2.2094. However, in the short run, Akoya Biosciences Inc’s stock first resistance to watch stands at $1.3000. Second resistance stands at $1.3400. The third major resistance level sits at $1.3800. If the price goes on to break the first support level at $1.2200, it is likely to go to the next support level at $1.1800. Should the price break the second support level, the third support level stands at $1.1400.
Akoya Biosciences Inc (NASDAQ: AKYA) Key Stats
Market capitalization of the company is 62.84 million based on 49,875K outstanding shares. Right now, sales total 81,670 K and income totals -55,370 K. The company made 16,640 K in profit during its latest quarter, and -15,650 K in sales during its previous quarter.
